uMed Company Profile

Background

uMed is a healthcare technology company founded in 2017, dedicated to accelerating clinical trials by enhancing accessibility for healthcare professionals and their patients. The company's mission is to bridge evidence gaps in life sciences research through a combination of real-world evidence (RWE) and patient-generated data. uMed's platform automates the clinical study process, creating patient registries that meet regulatory compliance and combine electronic health data with data captured from each patient, including genomic and biomarker samples. This enables healthcare providers to participate in multiple research programs simultaneously without increasing overhead or burdens on clinical teams.

Key Strategic Focus

uMed's strategic focus centers on:

Automating Clinical Research: Streamlining patient identification, screening, and engagement processes to reduce the workload on healthcare providers.

Enhancing Patient Engagement: Utilizing technology to facilitate patient participation in research, thereby improving data quality and study outcomes.

Expanding Global Reach: Establishing partnerships with healthcare institutions across the UK, US, Canada, and Australia to create a diverse and extensive network for clinical research.

Financials and Funding

uMed has demonstrated significant financial growth and has secured substantial funding to support its initiatives:

Annual Revenue: Estimated at $12.8 million.

Total Funding: Approximately $18 million raised through various funding rounds.

Recent Funding: A Series A round in July 2023 raised $12.3 million, with participation from investors such as Playfair Capital, AlbionVC, PharmStars, 11.2 Capital, and Delin Ventures.

Pipeline Development

uMed has developed several key initiatives to advance clinical research:

AccessPD: An interactive registry for Parkinson's Disease that has surpassed 1,000 participants, providing researchers with access to a large, diverse cohort ready for research opportunities.

AccessCMD: A cardiometabolic cohort that enrolled over 2,000 participants within four months, offering researchers access to novel endpoints and facilitating rapid data collection.

SnapACCESS: A platform designed to transform how pharmaceutical companies access and leverage patient data, initially focusing on diabetes and obesity research.

Technological Platform and Innovation

uMed's technological innovations include:

ACCESS Research Platform: Connects with a wide network of healthcare institutions, enabling the collection of crucial clinical outcomes and insights from deeply characterized consented patient cohorts.

Automated Patient Engagement: Utilizes technology to automate patient identification, screening, and engagement, reducing the workload on healthcare providers and enhancing study efficiency.

Leadership Team

uMed's leadership comprises experienced professionals dedicated to advancing clinical research:

Dr. Matt Wilson: Founder & CEO, leading the company's strategic vision and growth.

Chris Broderick: Chief Technology Officer, overseeing technological development and innovation.

Carlos Miragall: Chief Financial Officer, managing financial strategy and operations.

Anil Jina: Chief Medical Officer & President North America, guiding medical strategy and overseeing North American operations.

James Dunstan: Vice President of Commercial, responsible for commercial strategy and partnerships.

Abi Dhillon: Vice President of Commercial Operations, managing commercial operations and execution.

Neal Stine: General Manager US, leading US market operations and expansion.

Competitor Profile

Market Insights and Dynamics

The healthcare technology sector is experiencing rapid growth, driven by the increasing demand for efficient clinical trial processes and enhanced patient engagement solutions. uMed operates within this dynamic landscape, focusing on automating clinical research and improving patient participation.

Competitor Analysis

Key competitors in the healthcare technology and clinical research space include:

PicnicHealth: A venture capital-backed company based in San Francisco, specializing in patient-centric health data management.

ArisGlobal: A private equity-backed firm headquartered in Coral Gables, FL, offering cloud-based software solutions for the life sciences industry.

OM1: A Boston-based venture capital-backed company focusing on real-world data and evidence for healthcare.

Strategic Collaborations and Partnerships

uMed has established significant partnerships to enhance its capabilities:

Decisive Consulting: Collaborated to drive data-driven market access success in cardiometabolic and Parkinson’s disease research, offering pharmaceutical and biotech companies rapid access to unique, customizable data and expert guidance.

Global Parkinson’s Genetics Program (GP2): Partnered to support expansion of the international genetic initiative, providing access to genetic samples collected as part of their AccessPD Cohort Study.

Operational Insights

uMed's strategic considerations include:

Market Position: Positioned as a leader in automating clinical research processes and enhancing patient engagement.

Competitive Advantages: Offers a unique combination of real-world evidence and patient-generated data, enabling healthcare providers to participate in multiple research programs simultaneously without increasing overhead or burdens on clinical teams.

Strategic Opportunities and Future Directions

uMed's strategic roadmap includes:

Expansion of Patient Cohorts: Continuing to grow existing cohorts like AccessPD and AccessCMD to provide richer datasets for research.

Technological Enhancements: Further developing the ACCESS Research Platform to improve data collection and patient engagement capabilities.

Global Expansion: Strengthening partnerships with healthcare institutions worldwide to broaden the reach and impact of clinical research initiatives.